Generics & Biosimilars | Association for Accessible Medicines
AAM All Access Podcast - Dan Leonard speaks to David Gaugh (AAM), Jessica Daley (Premier Inc) and Steven Schondelmeyer (University of Minnesota).
  • Ariel
    AAM Calls on FTC to Investigate PBM Business Practices
    “A distinct set of PBM business practices have resulted in higher prices and delayed access to generics and biosimilars for patients,” said AAM CEO Dan Leonard.
  • AAM All Access Podcast
    Featured AAM All Access Podcast: Managing Drug Shortages
    What’s a drug shortage? AAM CEO Dan Leonard speaks to 3 eminent pharmacists, each with different insights into management and mitigation of drug shortages: David Gaugh (AAM), Jessica Daley (Premier Inc.) and Steven Schondelmeyer (University of Minnesota).
  • Ariel
    VETO Illinois HB 1780 Which Puts Patient Access to Generics at Risk!
    Generics drive patient savings, yet HB 1780 imposes new costs on patients who rely on generics access to life-saving treatments.
  • Markup Madness
    Who’s Profiting from Your Prescription?
    Unlike brand drugs where the manufacturer stands to profit the most, generic medicines are often exploited by middlemen that seize significant profits at the expense of patients and the companies that make the medicines.
  • GRx+Biosims 2022
    GRx+Biosims 2022 Early Bird Special
    Registration is open! Sign up now for the early bird discount and $500 off a GRx+Biosims conference full-pass registration! November 7-9, 2022 in North Bethesda, Maryland.
  • 2021 state savings map
    Generic Medicines Are Saving Your State Billions
    In 2020, generic and biosimilar medicines saved America's patients $338 billion. Find out how much your state saved with our interactive savings map.
  • AAM Voices of Access
    AAM Voices of Access
    Physicians, pharmacists, patients and caregivers across the country trust generics and biosimilars. Here are their stories, in their own words—along with perspectives from health care professionals and the AAM team.
  • Generics and Biosimilars are the Prescription for State Savings #Rx4StateSavings
    Prescription for State Savings
    State lawmakers can take meaningful action to lower brand prescription drug costs with the Prescription for State Savings. AAM outlines several solutions states could pursue.
  • AAM 2021 U.S. Generic and Biosimilar Medicines Savings Report. October 2021.
    AAM Encourages Congress to Protect Patient Savings
    Competition from lower-cost generics and biosimilars has successfully led to decades of savings for patients. AAM strongly opposes negotiations in Medicare that would jeopardize these savings.

Our Brands and Campaigns

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.